Welcome investors new and old! Feel free to as
Post# of 72447
Posted On: 04/19/2016 9:38:07 AM
Welcome investors new and old!
Feel free to ask real questions around here I will line you up with some easy reading. This is a great company with many major near term catalysts! There will be several that slither over from the other board from time to time to spread lies and down play news, we have just learned to poke at them a little then ignore them.
Start with company website:
http://cellceutix.com/
Then how about an easy timeline of events:
http://www.marketwired.com/AdvancedSearch/Adv...902f39c5c6
A list from clinical trials of our ongoing and complete trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Here is what we are talking about as far as near term catalysts:
- P top-line data (Phase 2)
- B-OM interim data (Phase 2)
- K top-line data (Phase 1)
- Start of B-ABSSSI (Phase 3)
- Start of B-UP (Phase 2, proof of concept)
- Start of K-ovarian (Phase 2)
- Fast track designation for B-ABSSSI
- ASM Microbe presentations (June 19-20)
Past milestones:
- QIDP designation for B-ABSSSI
- Fast track designation for B-OM
- Orphan drug designation for K-ovarian cancer
- Orphan drug designation for K-pancreatic cancer
- Orphan drug designation for K-retinoblastoma
- Rare pediatric disease designation for K-retinoblastoma
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 11 (750 mg/m2)
- K positive primary outcome (Phase 1)
- P positive primary outcome (Phase 1)
- Stable formulation of B at room temperature
- MTA extension on testing B in implanted devices
A few things to help you when reading around:
B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs
K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs
P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs
Our current FDA designations:
3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma
Feel free to ask real questions around here I will line you up with some easy reading. This is a great company with many major near term catalysts! There will be several that slither over from the other board from time to time to spread lies and down play news, we have just learned to poke at them a little then ignore them.
Start with company website:
http://cellceutix.com/
Then how about an easy timeline of events:
http://www.marketwired.com/AdvancedSearch/Adv...902f39c5c6
A list from clinical trials of our ongoing and complete trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Here is what we are talking about as far as near term catalysts:
- P top-line data (Phase 2)
- B-OM interim data (Phase 2)
- K top-line data (Phase 1)
- Start of B-ABSSSI (Phase 3)
- Start of B-UP (Phase 2, proof of concept)
- Start of K-ovarian (Phase 2)
- Fast track designation for B-ABSSSI
- ASM Microbe presentations (June 19-20)
Past milestones:
- QIDP designation for B-ABSSSI
- Fast track designation for B-OM
- Orphan drug designation for K-ovarian cancer
- Orphan drug designation for K-pancreatic cancer
- Orphan drug designation for K-retinoblastoma
- Rare pediatric disease designation for K-retinoblastoma
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 11 (750 mg/m2)
- K positive primary outcome (Phase 1)
- P positive primary outcome (Phase 1)
- Stable formulation of B at room temperature
- MTA extension on testing B in implanted devices
A few things to help you when reading around:
B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs
K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs
P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs
Our current FDA designations:
3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma
(1)
(1)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
If you try to defend yourself against lies of the board moderators your post will be deleted. Just like the board they claim to be better than!!! Watch who you trust especially the "long term investors" that support the real attackers!